Ropes & Gray Advises AvenCell Therapeutics in $112 Million Series B Funding

In The News
October 23, 2024

Ropes & Gray represented AvenCell Therapeutics in its $112 million Series B funding round led by global life sciences investor Novo Holdings. New investors F-Prime Capital, Eight Roads VenturesJapan, Piper Heartland Healthcare Capital and NYBC Ventures also participated in the round alongside founding investor Blackstone Life Sciences.

AvenCell is a leading clinical-stage cell therapy company. The new funding will accelerate clinical validation of AvenCell's proprietary Universal Switchable CAR-T cell therapy platform, for the treatment of a wide range of hematologic malignancies and auto-immune diseases.

The deal team was led by venture capital & emerging companies partner Rajarshi Banerjee and life sciences partner Michael Beauvais, and included litigation & enforcement partner Lisa Kaltenbrunner and finance partner Milap Patel.